Anebulo Pharmaceuticals, Inc. · LSX:A3CM1D

Anebulo Pharmaceuticals, Inc. financial statements

Anebulo Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue00000
Research and development4.30M3.55M5.60M2.96M2.27M150.0K
Selling, general and administrative4.92M4.75M6.18M3.87M1.34M140.1K
Operating income-9.22M-8.31M-11.8M-6.83M-3.61M-173.4K
Depreciation and amortization382.0K151.2K11.8K6.83M3.61M1.04M
EBITDA-8.84M-8.16M-11.8M-1740866.8K
Interest expense400.0K200.0K07.33K11.8K1.29K
Income before tax-8.48M-8.20M-11.7M-6.83M-3.61M-174.6K
Income tax-104.2K-12.9K10.7K-1.04K
Net income-8.48M-8.20M-11.7M-6.83M-30.3M-174.6K
Earnings per share, basic-0.25-0.32-0.470.29-2.83-0.01
Earnings per share, diluted-0.25-0.32-0.470.29-2.83

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents11.6M3.09M11.2M14.5M20.0M3.02M
Receivables73.2K3.50K
Inventory-4
Current assets12.0M3.51M11.7M15.6M21.7M3.03M
Total assets12.1M4.07M11.7M15.6M21.7M3.03M
Accounts payable224.2K156.4K534.5K380.8K110.0K0
Current liabilities224.2K260.6K1.07M512.5K241.6K223.9K
Total debt201.3K
Total liabilities487.7K260.6K1.07M512.5K241.6K223.9K
Shareholders' equity11.7M3.81M10.6M15.1M21.4M2.80M
Shares outstanding41.1M25.9M25.6M23.3M23.3M23.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-6.35M-8.09M-9.68M-5.44M-4.87M-150.8K
Capital spending-3-10-40-2
Free cash flow-6.35M-8.09M-9.68M-5.44M-4.87M-150.8K
Cash from financing14.9M-62.4K6.38M6.38M21.8M3.18M
Dividends paid-8.21M
Share buybacks8.21M3.00M
Change in cash8.53M-8.15M-3.30M-5.44M17.0M3.02M